Green Planet Bio Engineering Co. Ltd. - Quarter Report: 2017 September (Form 10-Q)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, DC
20549
_______________________
FORM
10-Q
_______________________
(Mark
One)
☒
|
Quarterly Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
|
For the quarterly
period ended September 30, 2017
or
☐
|
Transition Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
|
For the transition
period from___________ to ____________
Commission file
number 000-52622
GREEN
PLANET BIOENGINEERING CO., LTD.
(Exact Name of
Registrant as Specified in its charter)
Delaware
|
|
37-1532842
|
(State or other
jurisdiction of
|
|
(I.R.S.
Employer
|
incorporation or
organization)
|
|
Identification
No.)
|
|
|
|
20807
Biscayne Blvd., Suite 203,
|
|
|
Aventura,
Florida
|
|
33180
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
(786)
279-2900
(Registrant’s
telephone number, including area code)
Indicate by check
mark whether the registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period
that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days.
Yes ☒ No ☐
Indicate by check
mark whether the registrant has submitted electronically and posted
on its corporate Web site, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of
Regulation S-T (§232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the
registrant was required to submit and post such
files). Yes ☐ No ☐
Indicate by
checkmark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated
filer,” “accelerated filer” and “smaller
reporting company” in Rule 12b-2 of the Exchange Act. (Check
one):
Large accelerated
filer
|
☐
|
Accelerated
filer
|
☐
|
Non-accelerated
filer
|
☐
|
Smaller reporting
company
|
☒
|
(Do not check if a
smaller company)
|
|
|
|
Indicate by check
mark whether the registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act)
Yes ☒ No ☐
The
number of shares of common stock outstanding as of October 27, 2017
was 20,006,402.
TABLE OF CONTENTS
|
|
Page
Number
|
PART I
FINANCIAL INFORMATION
|
|
|
|
|
|
Item
1.
|
Financial
Statements
|
1
|
|
|
|
|
Condensed
Balance Sheets as of September 30, 2017 (Unaudited) and December
31, 2016
|
1
|
|
|
|
|
Condensed
Statements of Operations for the Three and Nine Months Ended
September 30, 2017 and 2016
|
2
|
|
|
|
|
Condensed
Statements of Cash Flows for the Nine Months Ended September 30,
2017 and 2016
|
3
|
|
|
|
|
Notes
to the Condensed Financial Statements
|
4
|
|
|
|
Item
2.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
6
|
|
|
|
Item
3.
|
Quantitative
and Qualitative Disclosures about Market Risk
|
7
|
|
|
|
Item
4.
|
Controls
and Procedures
|
7
|
|
|
|
PART II OTHER
INFORMATION
|
|
|
|
|
|
Item
1.
|
Legal
Proceedings
|
8
|
|
|
|
Item
2.
|
Unregistered
Sales of Equity Securities and Use of Proceeds
|
8
|
|
|
|
Item
3.
|
Defaults
upon Senior Securities
|
8
|
|
|
|
Item
4.
|
Reserved
|
8
|
|
|
|
Item
5.
|
Other
Information
|
8
|
|
|
|
Item
6.
|
Exhibits
|
8
|
|
|
|
SIGNATURES
|
9
|
i
INTERIM FINANCIAL STATEMENTS
The
unaudited interim financial statements have been prepared in
accordance with generally accepted accounting principles in the
United States for interim financial information and with the
instructions under Regulation S-X of the Securities and Exchange
Commission (“SEC”) Form 10-Q. Accordingly, they do not
include all the information and footnotes required by generally
accepted accounting principles for complete financial statements.
Therefore, these financial statements should be read in conjunction
with the Company’s audited financial statements and notes
thereto for the year ended December 31, 2016.
The
financial statements included herein are unaudited; however, they
contain all normal recurring accruals and adjustments that, in the
opinion of management, are necessary to present fairly the
Company’s financial position as of the period reporting date,
and the results of its operations and cash flows for the fiscal
period end. The results of operations for the fiscal period end are
not necessarily indicative of the results to be expected for future
quarters or the full fiscal year.
FORWARD-LOOKING
STATEMENTS
This
Quarterly Report on Form 10-Q contains forward-looking statements
within the meaning of Section 21E of the Securities Exchange Act of
1934. These statements involve risks and uncertainties, including,
among other things, statements regarding our business strategy,
future revenues and anticipated costs and expenses. Such
forward-looking statements include, among others, those statements
including the words
“expects,”“anticipates,”
“intends,” “believes,” “may,”
“will,” “should,” “could,”
“plans,” “estimates,” and similar language
or negative of such terms. Our actual results may differ
significantly from those projected in the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, those discussed in
Item 2 “Management’s Discussion and Analysis of
Financial Condition and Results of Operations.” You are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date of this report.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we do not know whether
we can achieve positive future results, levels of activity,
performance, or goals. Actual events or results may differ
materially. We undertake no obligation to publicly release any
revisions to the forward-looking statements or reflect events or
circumstances taking place after the date of this
document.
ii
PART
I
FINANCIAL
INFORMATION
ITEM
1.
FINANCIAL
STATEMENTS
Green
Planet Bioengineering Co., Ltd.
Condensed
Balance Sheets
|
September
30,
|
December
31,
|
|
2017
|
2016
|
|
(Unaudited)
|
(Audited)
|
ASSETS
|
|
|
Current
assets
|
|
|
Cash
and cash equivalents
|
$-
|
$-
|
TOTAL CURRENT ASSETS / TOTAL ASSETS
|
$-
|
$-
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
|
|
LIABILITIES
|
|
|
Current
liabilities
|
|
|
Accounts
payable
|
$
-
|
$-
|
Accrued
liabilities
|
6,500
|
11,500
|
Amount
due to a related party
|
200,762
|
171,914
|
TOTAL CURRENT LIABILITIES / TOTAL LIABILITIES
|
$207,262
|
$183,414
|
STOCKHOLDERS’ DEFICIT
|
|
|
Preferred
stock: par value of $0.001 per share
|
|
|
Authorized:
10,000,000 shares at September 30, 2017 and December 31,
2016
|
|
|
Issued
and outstanding: 0 shares at September
30, 2017 and December 31, 2016
|
-
|
-
|
Common
stock: par value of $0.001 per share
|
|
|
Authorized:
250,000,000 shares at September
30, 2017 and December 31, 2016
|
|
|
Issued
and outstanding: 20,006,402 shares at September
30, 2017 and December 31, 2016
|
20,006
|
20,006
|
Additional
paid-in-capital
|
609,614
|
609,614
|
Accumulated
deficit
|
(836,882)
|
(813,034)
|
TOTAL STOCKOLDERS’ DEFICIT
|
$(207,262)
|
$(183,414)
|
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT
|
-
|
-
|
See Notes to the
Condensed Financial Statements
1
Green
Planet Bioengineering Co., Ltd.
Condensed
Statements of Operations
(Unaudited)
|
Three
months ended September 30,
|
Nine
months ended September 30,
|
||
|
2017
|
2016
|
2017
|
2016
|
|
|
|
|
|
Administrative
expenses
|
$(11,703)
|
$(11,179)
|
$(23,848)
|
$(23,679)
|
Loss
before taxes
|
(11,703)
|
(11,179)
|
(23,848)
|
(23,679)
|
Provision
for income taxes
|
-
|
-
|
-
|
-
|
Net
loss
|
$(11,703)
|
$(11,179)
|
$(23,848)
|
$(23,679)
|
Earnings
per share
|
|
|
|
|
-Basic
and diluted
|
$*
|
$*
|
$*
|
$*
|
Weighted
average number of shares outstanding
|
|
|
|
|
-Basic
and diluted
|
20,006,402
|
20,006,402
|
20,006,402
|
20,006,402
|
*
Less
than $.01, per share
See Notes to the
Condensed Financial Statements
2
Green
Planet Bioengineering Co., Ltd.
Condensed
Statements of Cash Flows
(Unaudited)
|
Nine
months ended September 30,
|
|
|
2017
|
2016
|
Cash flows from operating activities
|
|
|
Net
loss
|
$(23,848)
|
$(23,679)
|
Changes
in operating assets and liabilities:
|
|
|
Accounts
payable
|
-
|
5,700
|
Accrued
liabilities
|
(5,000)
|
(6,450)
|
Amount
due to a related party
|
28,848
|
24,429
|
Net
cash flows used by operating activities
|
-
|
-
|
|
|
|
Cash flows from investing activities
|
-
|
-
|
|
|
|
Cash flows from financing activities
|
-
|
-
|
|
|
|
Net
decrease in cash and cash equivalents
|
-
|
-
|
Cash
and cash equivalents – beginning of period
|
-
|
-
|
Cash
and cash equivalents – end of period
|
$-
|
$-
|
Supplemental
disclosures for cash flow information:
|
|
|
Cash
paid for interest
|
$-
|
$-
|
Cash
paid for income taxes
|
$-
|
$-
|
See Notes to the
Condensed Financial Statements
3
Green
Planet Bioengineering Co., Ltd
Notes
to the Condensed Financial Statements
(Unaudited)
1.
Organization
Mondo
Acquisition II, Inc. was incorporated in the State of Delaware on
October 30, 2006 and changed the name to Green Planet
Bioengineering Co., Ltd. (“Company”) on October 2,
2008. In October 2008, the Company acquired Elevated Throne
Overseas Ltd, incorporated in British Virgin Islands, and its
subsidiaries which was subsequently divested to One Bio, Corp
(“ONE”) on April 14, 2010.
In
March 2012, the Company became a subsidiary of Global Fund Holdings
Corp. (“Global Funds”) an Ontario, Canada
corporation.
The
Company operates as a public organized shell corporation with the
purpose to acquire or merge with an existing business operation.
The Company’s activities are subject to significant risks and
uncertainties, as their ability to implement and execute future
business plans and generate sufficient business revenue is directly
influenced by their ability to secure adequate financing or find
profitable business opportunities.
2.
Summary of significant accounting policies
Basis of Presentation
The
financial statements of the Company have been prepared in
accordance with generally accepted accounting principles in the
United States of America (“U.S. GAAP”) and are
unaudited; however, they contain all normal recurring accruals and
adjustments that, in the opinion of management, are necessary to
present fairly the Company’s financial position as of the
period reporting date, and the results of its operations and cash
flows for the fiscal period end. The results of operations for the
fiscal period end are not necessarily indicative of the results to
be expected for future quarters or the full fiscal
year.
Use of Estimates
The
preparation of financial statements in accordance with U.S. GAAP
requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and the disclosure
of contingent assets and liabilities as of the date of the
financial statements and the reported amounts of revenue and
expenses for the years reported. Actual results could differ from
those estimates. Significant items that require estimates were
accruals of liabilities.
Cash and cash equivalents
Cash
and cash equivalents include all cash, deposits in banks and other
highly liquid investments with initial maturities of three months
or less to be cash equivalents. Balances of cash and cash
equivalents in financial institutions may at times exceed the
government-insured limits.
Earnings per share
Earnings
per share is reported in accordance with FASB ASC Topic 260
“Earnings per
Share” which requires dual presentation of basic
earnings per share (“EPS”) and diluted EPS on the face
of all statements of earnings, for all entities with complex
capital structures. Diluted EPS reflects the potential dilution
that could occur from common shares issuable through the exercise
or conversion of stock options, restricted stock awards, warrants
and convertible securities. In certain circumstances, the
conversion of these options, warrants and convertible securities
are excluded from diluted EPS if the effect of such inclusion would
be anti-dilutive. Fully diluted EPS is not provided, when the
effect is anti-dilutive. When the effect of dilution on loss per
share is anti-dilutive, diluted loss per share equals the loss per
share.
Fair Value Measurements
FASB
ASC Topic 820, “Fair Value
Measurements and Disclosures” defines fair value,
establishes a framework for measuring fair value in accordance with
U.S. GAAP, and expands disclosures about fair value measurements.
Investment measured and reported at fair value are classified and
disclosed in one of the following hierarchy:
4
2. Summary of Significant Accounting Policies –
continued
Level 1
- Quoted prices are available in active markets for identical
investments as of the period reporting date.
Level 2
- Pricing inputs are other than quoted prices in active markets,
which are either directly or indirectly observable as of the
reporting date, and fair value is determined through the use of
models or other valuation methodologies.
Level 3
- Pricing inputs are unobservable for the investment and included
situations where there is little, if any, market activity for the
investment. The inputs into the determination of fair value require
significant management judgment or estimation.
Recent Changes in Accounting Standards
In August 2014, the FASB issued ASU No. 2014-15 "Presentation of
Financial Statements-Going Concern." The provisions of ASU No.
2014-15 require management to assess an entity’s liability to
continue as a going concern by incorporating and expanding upon
certain principles that are currently in U.S. audit standards.
Specifically, the amendments (1) provide a definition of the term
substantial doubt, (2) require evaluation of every reporting period
including interim periods, (3) provide principles for considering
the mitigating effect of management’s plans, (4) require
certain disclosures when substantial doubt is alleviated as a
result of consideration of management’s plans, (5) require an
express statement and other disclosures when substantial doubt in
not alleviated, and (6) require an assessment for a period of one
year after the date that the financial statements are issued (or
available to be issued). The amendments in this ASU are
effective for the annual period ending after December 15, 2016, and
for annual periods and interim periods thereafter. The Company
believes that the adoption of ASU No. 2014-15 does not have a
material impact on the Company’s financial
statements.
3. Going Concern
The
financial statements have been prepared assuming that the Company
will continue as a going concern. The Company is currently a public
shell corporation and has no current business activity. The
Company’s ability to continue as a going concern is dependent
on continued support from Global Funds, the majority
stockholder.
4. Amount Due to a Related Company
The
Company relies on a related company to advance funds to finance its
operating expenses. The amounts advanced are interest-free,
unsecured and are repayable upon demand.
5. Preferred stock / Common stock
Preferred stock
The Company is authorized under its Articles of Incorporation to
issue 10,000,000 shares of Series A preferred stock with a par
value of $0.001 per share. Each share of the Company’s
preferred stock provides the holder with the right to vote 1,000
votes on all matters submitted to a vote of the stockholders of the
Company and is convertible into 1,000 shares of the Company’s
common stock. The preferred stock is non-participating and carries
no dividend.
The company does not have any issued shares of the preferred stock
as of September 30, 2017 and 2016.
Common
stock
The Company is authorized to issue 250,000,000 shares of common
stock with a par value of $0.001 per share. During the three
and nine months ended September 30, 2017, the Company did
not issue any shares of common stock or warrants.
6.
Stock-based compensation
There
was no non-cash stock-based compensation recognized for the three
and nine
months ended September 30, 2017 and 2016.
5
ITEM
2.
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
General Overview
The
Company operates as a public reorganized corporation with the
business purpose to acquire or merge with an existing business
operation.
Results of Operations and Financial Condition for the three and
nine months ended September 30, 2017, as compared to the three and
nine months ended September 30, 2016
The
Company had no active business operations for the periods ended
September 30, 2017 and September 30, 2016. Expenses consist of
accounting, legal and filing fees.
Liquidity and capital resources
The
Company had no active business operations for the nine months ended
September 30, 2017 and 2016. Accordingly, all of the
Company’s cash flows were provided by a related
entity.
Risk factors
The
Company’s critical accounting policies are still being
applied despite the fact that the Company has no ongoing business
operations.
Significant Estimates
The
preparation of financial statements in conformity with generally
accepted accounting principles in the United States of America
requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, as well as the
disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of expenses during
the reporting period. Actual results could differ from those
estimates.
Critical Accounting Policies
We
prepare our financial statements in conformity with generally
accepted accounting principles in the United States of America. As
such, we are required to make certain estimates, judgments and
assumptions that we believe are reasonable based upon the
information available. These estimates, judgments and assumptions
affect the reported amounts of assets and liabilities at the date
of the financial statements and the reported amounts of revenue and
expenses during the periods presented. Actual results could be
different than those estimates.
Off-Balance Sheet Arrangements
We do
not have any off-balance sheet arrangements that have or are
reasonably likely to have a current or future effect on our
financial condition, changes in financial condition, revenues or
expenses, results of operations, liquidity, capital expenditures or
capital resources that is material to investors.
Market Risks
There
has been no material change in market risks since our last Annual
Report on Form 10-K for the year ended December 31,
2016.
6
ITEM
3.
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not
Applicable
ITEM
4.
CONTROLS
AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our
management, with the participation of our chief executive officer
and chief financial officer, evaluated the effectiveness of our
disclosure controls and procedures pursuant to Rule 13a-15 under
the Securities Exchange Act of 1934, as amended (Exchange Act), as
of the end of the period covered by this Quarterly Report on Form
10-Q.
Based
on this evaluation, our chief executive officer and chief
financial officer concluded that, as of the fiscal period end, our
disclosure controls and procedures are designed at a reasonable
assurance level and are effective to provide reasonable assurance
that information we are required to disclose in reports that we
file or submit under the Exchange Act is recorded, processed,
summarized, and reported within the time periods specified in the
SEC’s rules and forms, and that such information is
accumulated and communicated to our management, including our chief
executive officer and chief financial officer, as appropriate, to
allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There
were no changes in our internal control over financial reporting
that occurred during the quarter ended September 30, 2017 that have
materially affected, or are reasonably likely to materially affect,
our internal control over financial reporting.
Limitations on Effectiveness of Controls and
Procedures
In
designing and evaluating the disclosure controls and procedures,
management recognizes that any controls and procedures, no matter
how well designed and operated, can provide only reasonable
assurance of achieving the desired control objectives. In addition,
the design of disclosure controls and procedures must reflect the
fact that there are resource constraints and that management is
required to apply its judgment in evaluating the benefits of
possible controls and procedures relative to their
costs.
7
PART
II
OTHER
INFORMATION
ITEM
1.
LEGAL
PROCEEDINGS
None
ITEM
2.
UNREGISTERED
SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
None
ITEM
3.
DEFAULTS
UPON SENIOR SECURITIES
None
ITEM
4.
RESERVED
ITEM
5.
OTHER
INFORMATION
None
31 Certification
of Chief Executive Officer and Chief Financial Officer pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002
32 Certification
of Chief Executive Officer and Chief Financial Officer pursuant to
18 U.S.C. Section 1350
8
SIGNATURES
Pursuant to the
requirements of Section 13 or 15(d) of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned; thereunto duly authorized this 27th
day of October 2017.
|
GREEN PLANET
BIOENGINEERING CO., LTD.
|
|
|
|
|
|
|
Date: October 27,
2017
|
By:
|
/s/ Jordan Weingarten
|
|
|
|
Jordan
Weingarten President and Chief Financial Officer
|
|
|
|
(Principal
Executive Officer and
Principal Financial
Officer)
|
|
9